FDA 483 - ARx LLC - March 29, 2019

An FDA inspection of ARX, LLC, a contract human drug manufacturer in Glen Rock, PA, revealed significant deficiencies across its quality control and manufacturing operations. The firm failed to establish test method sensitivity, maintain proper stability programs, ensure data integrity, and adequately manage equipment cleaning and calibration. These findings indicate a lack of robust quality systems necessary for drug product manufacturing.